User profiles for Ian M Collins
Ian M CollinsDeakin University Verified email at deakin.edu.au Cited by 777 |
Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations
STUDY QUESTION Do women with BRCA1 or BRCA2 mutations have reduced ovarian
reserve, as measured by circulating anti-Müllerian hormone (AMH) concentration? SUMMARY …
reserve, as measured by circulating anti-Müllerian hormone (AMH) concentration? SUMMARY …
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
…, CS Karapetis, M Singh, IM Collins… - The Journal of …, 2023 - Wiley Online Library
Cancer of unknown primary (CUP) is a syndrome defined by clinical absence of a primary
cancer after standardised investigations. Gene expression profiling (GEP) and DNA …
cancer after standardised investigations. Gene expression profiling (GEP) and DNA …
[HTML][HTML] Assessing and managing breast cancer risk: clinicians' current practice and future needs
Decision support tools for the assessment and management of breast cancer risk may
improve uptake of prevention strategies. End-user input in the design of such tools is critical to …
improve uptake of prevention strategies. End-user input in the design of such tools is critical to …
[PDF][PDF] Teletrials: implementation of a new paradigm for clinical trials
Cancer is a considerable health issue, with 395 new cancer diagnoses per day. 3 The regional
mortality gap in cancer remains. 4 Between 2000 and 2010, patients in regional and rural …
mortality gap in cancer remains. 4 Between 2000 and 2010, patients in regional and rural …
[HTML][HTML] Targeting homologous recombination deficiency in uterine leiomyosarcoma
…, JD Power, T Meniawy, TH Tan, IM Collins… - Journal of Experimental …, 2023 - Springer
Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological
malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations …
malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations …
[HTML][HTML] iPrevent®: a tailored, web-based, decision support tool for breast cancer risk assessment and management
IM Collins, A Bickerstaffe, T Ranaweera… - Breast cancer research …, 2016 - Springer
We aimed to develop a user-centered, web-based, decision support tool for breast cancer
risk assessment and personalized risk management. Using a novel model choice algorithm, …
risk assessment and personalized risk management. Using a novel model choice algorithm, …
[PDF][PDF] Do BRCA1 and BRCA2 Mutation Carriers Have Earlier Natural Menopause Than Their Noncarrier Relatives? Results From the Kathleen Cuningham …
IM Collins, RL Milne, SA McLachlan… - Journal of clinical …, 2013 - researchgate.net
… Collins, Sue Anne McLachlan, Prue Weideman, Kate E. Birch, and Kelly-Anne Phillips,
Peter MacCallum Cancer Centre; Ian M. Collins, Roger L. Milne, Sue Anne McLachlan …
Peter MacCallum Cancer Centre; Ian M. Collins, Roger L. Milne, Sue Anne McLachlan …
Preventing breast and ovarian cancers in high‐risk BRCA1 and BRCA2 mutation carriers
IM Collins, RL Milne, PC Weideman… - Medical Journal of …, 2013 - Wiley Online Library
Objective: To estimate the prevalence of the use of cancer risk‐reducing measures among
Australian BRCA1 and BRCA2 mutation carriers. Design, setting and participants: …
Australian BRCA1 and BRCA2 mutation carriers. Design, setting and participants: …
Women's preferences for selective estrogen reuptake modulators: an investigation using protection motivation theory
Objective Selective estrogen receptor modulators (SERMs) reduce breast cancer risk by 38%.
However, uptake is low and the reasons are not well understood. This study applied …
However, uptake is low and the reasons are not well understood. This study applied …
[HTML][HTML] Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
…, B Gao, CS Karapetis, M Singh, IM Collins… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
Background Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers
where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited …
where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited …